Professional
Added to YB: 2025-01-09
Pitch date: 2025-01-07
NVO [bullish]
Novo Nordisk A/S
-40.14%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 83.83
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Protean Funds Scandinavia AB Portfolio Holdiing: Novo Nordisk A/S
NVO: Cagrisema phase III study miss caused 20% drop in Dec. Pharma stocks priced on 5+ year growth potential, so next-gen product not exceeding competitor is significant. Questions remain on study design & dosage. Still attractive for valuation, cash flows, innovation & shareholder returns. -0.5% net loss for year despite volatility.
Read full article (2 min)